CADL Candel Therapeutics Inc
2,354
$11.50
$1.20
(9.45%)
| Watchers | 2,354 |
| 52-Wk Low | $0.66 |
| 52-Wk High | $14.30 |
| Market Cap | $342.06M |
| Volume | 840,597.00 |
| 52-Wk High | $14.30 |
| 52-Wk Low | $0.66 |
Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early DetectionPR Newswire • 4 days ago
Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection PR Newswire VANCOUVER, BC, May...
Share to Feed
Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb PR Newswire VANCOUVER, BC, May 9, 2024 USA...
Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb PR Newswire VANCOUVER, BC, May 9, 2024 USA...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Candel Therapeutics sees surge in shares amid robust volume, buoyed by promising interim data from CAN-2409 phase 2 trial for non-metastatic prostate cancer. Exciting developments continue with...
Acciones al alza
Tevogen Bio Holdings (NASDAQ:TVGN) ganaron un 92,75% para establecerse en los 5,05 d lares durante la sesi n del pre-market del jueves.
Candel Therapeutics (NASDAQ:CADL) avanzaron un...
Updated positive interim data showed notable improvements in estimated median overall survival of 28.8 months after experimental treatment with CAN-2409 versus only 12.5 months in control group in...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
On track for topline data from CAN-2409 phase 3 in localized intermediate/high risk prostate cancer, expected in Q4 2024Results from ongoing, first-in-human, phase 1b clinical trial of CAN-3110, in...